Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• Seven analysts give Ironwood Pharmaceuticals a consensus “Moderate Buy” rating: four hold, two buy and one strong buy. The average one-year price target is $6.23.
• Ironwood beat Q3 estimates, reporting adjusted EPS of $0.36 versus $0.32 expected and revenue of $133.04 million versus $119.99 million expected.
• The company raised its 2026 revenue outlook to $485 million–$510 million, above the roughly $470.5 million consensus, and increased its EBITDA outlook.

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have earned an average rating of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $6.23.

A number of equities research analysts have recently commented on IRWD shares. Zacks Research cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 30th. Weiss Ratings upgraded shares of Ironwood Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday, October 8th. Jefferies Financial Group raised shares of Ironwood Pharmaceuticals to a "hold" rating in a research report on Friday, September 25th. Finally, Wall Street Zen upgraded Ironwood Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday.

More Ironwood Pharmaceuticals News

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Ironwood reported Q3 adjusted earnings of $0.36 per share, above analyst expectations, while net income rose 49% year over year. It raised 2026 revenue guidance to $485 million–$510 million, above the roughly $470.5 million consensus, and increased its EBITDA outlook. Management also cited stronger Linzess sales expectations and profitability. Ironwood Q3 net income rises and outlook increases
• Neutral Sentiment: Revenue commentary was inconsistent: one Zacks headline described revenue as missing expectations, while reported figures of $133.04 million exceeded the estimate of $119.99 million cited elsewhere. Zacks Q3 earnings and outlook coverage

Ironwood Pharmaceuticals Stock Performance

NASDAQ:IRWD opened at $4.39 on Friday. The company has a market capitalization of $725.40 million, a price-to-earnings ratio of 4.88 and a beta of 0.25. The stock has a 50-day simple moving average of $3.91 and a 200 day simple moving average of $3.97. Ironwood Pharmaceuticals has a one year low of $1.88 and a one year high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.04. Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%. The company had revenue of $133.04 million during the quarter, compared to the consensus estimate of $119.99 million. On average, equities research analysts forecast that Ironwood Pharmaceuticals will post 1.10 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in IRWD. Arrowstreet Capital Limited Partnership grew its position in Ironwood Pharmaceuticals by 724.5% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,397,242 shares of the biotechnology company's stock worth $11,924,000 after buying an additional 2,985,181 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Ironwood Pharmaceuticals by 529.3% during the first quarter. Dimensional Fund Advisors LP now owns 2,082,055 shares of the biotechnology company's stock valued at $7,307,000 after acquiring an additional 1,751,219 shares in the last quarter. Hillsdale Investment Management Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 6.9% during the 1st quarter. Hillsdale Investment Management Inc. now owns 1,236,628 shares of the biotechnology company's stock valued at $4,341,000 after purchasing an additional 80,250 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at $3,982,000. Finally, Ritholtz Wealth Management grew its holdings in shares of Ironwood Pharmaceuticals by 130.8% in the 3rd quarter. Ritholtz Wealth Management now owns 831,091 shares of the biotechnology company's stock worth $3,299,000 after acquiring an additional 470,997 shares during the period.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines intended to treat disorders affecting the gastrointestinal tract, with an emphasis on conditions involving gut motility and visceral sensitivity.

Ironwood's principal commercial product is Linzess (linaclotide), marketed in the United States in collaboration with AbbVie. Linzess is approved for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.